BofA analyst Allen Lutz downgraded Omnicell (OMCL) to Neutral from Buy with a price target of $57, up from $44. The market is pricing in a clear return to growth for Omnicell’s Product business with shares up 30%, notes the analyst. However, while product extensions like XTAmplify can help drive incremental sales, visibility into growth is low, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL: